Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis

Mary N. Burtnick,a,b Teresa L. Shaffer,a,b Brittany N. Ross,c Laura A. Muruato,c Elena Sbrana,d David DeShazer,e Alfredo G. Torres,c Paul J. Brett,a,b

aDepartment of Microbiology and Immunology, University of South Alabama, Mobile, Alabama, USA
bDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA
cDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA
dDepartment of Pathology, Autopsy Division, University of Texas Medical Branch, Galveston, Texas, USA
eBacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA

ABSTRACT Burkholderia pseudomallei, the etiologic agent of melioidosis, causes severe disease in humans and animals. Diagnosis and treatment of melioidosis can be challenging, and no licensed vaccines currently exist. Several studies have shown that this pathogen expresses a variety of structurally conserved protective antigens that include cell surface polysaccharides and cell-associated and cell-secreted proteins. Based on those findings, such antigens have become important components of the subunit vaccine candidates that we are currently developing. In the present study, the 6-deoxyheptan capsular polysaccharide (CPS) from B. pseudomallei was purified, chemically activated, and covalently linked to recombinant CRM197 diphtheria toxin mutant (CRM197) to produce CPS-CRM197. Additionally, tandem nickel-coobalt affinity chromatography was used to prepare highly purified recombinant B. pseudomallei Hcp1 and TssM proteins. Immunization of C57BL/6 mice with CPS-CRM197 produced high-titer IgG and opsonizing antibody responses against the CPS component of the glycoconjugate, while immunization with Hcp1 and TssM produced high-titer IgG and robust gamma interferon-secreting T cell responses against the proteins. Extending upon these studies, we found that when mice were vaccinated with a combination of CPS-CRM197 and Hcp1, 100% of the mice survived a lethal inhalational challenge with B. pseudomallei. Remarkably, 70% of the survivors had no culturable bacteria in their lungs, livers, or spleens, indicating that the vaccine formulation had generated sterilizing immune responses. Collectively, these studies help to better establish surrogates of antigen-induced immunity against B. pseudomallei as well as provide valuable insights toward the development of a safe, affordable, and effective melioidosis vaccine.

KEYWORDS Burkholderia pseudomallei, Hcp1, capsule, glycoconjugate, immunity, inhalation, melioidosis, mouse, protection, vaccines

Melioidosis is an emerging infectious disease that is being increasingly recognized in tropical regions around the world. While it is known to be endemic in at least 48 different countries in Southeast Asia, South Asia, the Middle East, Africa, Central America, and South America, current models predict that the disease is probably endemic in 34 additional countries where it is yet to be reported (1). Underrecognition of melioidosis is due, in part, to the fact that most cases occur in resource-poor countries with large rural populations and limited microbiological laboratory capabilities (2). Since the clinical presentations of melioidosis are diverse, ranging from skin

Received 6 October 2017 Returned for modification 23 October 2017 Accepted 30 October 2017 Accepted manuscript posted online 6 November 2017 Citation Burtnick MN, Shaffer TL, Ross BN, Muruato LA, Sbrana E, DeShazer D, Torres AG, Brett PJ. 2018. Development of subunit vaccines that provide high-level protection and sterilizing immunity against acute inhalational melioidosis. Infect Immun 86:e00724-17. https://doi.org/10.1128/IAI.00724-17.

Editor Manuela Raffatellu, University of California San Diego School of Medicine

Copyright © 2017 Burtnick et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Mary N. Burtnick, mburtnick@med.unr.edu, or Paul J. Brett, pbrett@med.unr.edu.

* Present address: Laura A. Muruato, Baylor College of Medicine, Houston, Texas, USA.
abscesses to acute pneumonia and septicemia, diagnosis can be difficult. In 2015, the estimated total global burden of human melioidosis was \( \sim 165,000 \) cases with \( \sim 89,000 \) deaths, which is equivalent to the number of deaths attributed to measles and exceeds the levels of leptospirosis and dengue virus infection, underscoring the potential impact of the disease worldwide (1).

*Burkholderia pseudomallei*, the etiologic agent of melioidosis, is a facultative intracellular Gram-negative bacterium that can be isolated from environmental niches such as rice paddies, still or stagnant waters, and moist soils in areas where melioidosis is endemic. Humans can acquire *B. pseudomallei* infections through percutaneous inoculation via skin abrasions during occupational or recreational exposure, inhalation of bacteria in aerosolized dust or water, or ingestion of contaminated water (3, 4). Most natural infections occur in individuals with one or more risk factors, such as diabetes, alcoholism, chronic pulmonary disease, chronic renal disease, or thalassemia (5–8). At present, the association between route of infection and the clinical manifestations of melioidosis has not been clearly defined. Recent studies, however, have demonstrated a link between inhalation of aerosolized *B. pseudomallei* during severe weather events and pneumonia (9–12). Notably, over half of all melioidosis cases present as pneumonia, which can range from mild to severe disease (13).

In addition to being an important public health concern, *B. pseudomallei* is considered a potential biological weapon and is currently categorized as a tier 1 select agent by the U.S. Centers for Disease Control and Prevention (14, 15). In the event of an intentional release, it is believed that the most likely mode of dissemination would be via infectious aerosols that would lead to respiratory disease. Since *B. pseudomallei* is intrinsically resistant to many conventionally used antibiotics, treatment of melioidosis can be complicated. For culture-confirmed cases, the currently recommended antibiotic regimens are lengthy and typically involve a minimum of 2 weeks of intravenous therapy followed by up to 6 months of oral therapy (13). The ability of *B. pseudomallei* to persist inside host cells makes eradication of infections difficult, and even with appropriate chemotherapeutic intervention, relapse is possible (13). Furthermore, re-infection with a different *B. pseudomallei* strain can occur following successful treatment. At present, there are no human vaccines available for immunization against melioidosis. Because of these challenges, the development of medical countermeasures to combat melioidosis has become a priority in recent years (16).

An ideal melioidosis vaccine would be one that provides long-term protection against the most severe forms of the disease, namely, acute pneumonia and septicemia, and broad-spectrum protection against multiple *B. pseudomallei* strains. Several different live-attenuated vaccine strains as well as *B. pseudomallei*-derived outer membrane vesicles (OMVs) have been evaluated in preclinical studies and shown to confer significant protection in animal models of melioidosis (17–20). There are, however, important safety concerns associated with these types of vaccines. Numerous studies have also shown that *B. pseudomallei* expresses a variety of structurally conserved protective antigens. These antigens include cell surface polysaccharides (e.g., 6-deoxyheptan capsular polysaccharide [CPS] and lipopolysaccharides), cell-associated proteins (e.g., LolC, OmpA, OmpW, and FlIC), and secreted proteins (e.g., BopA, BimA, FlgL, and MprA) (16, 21–29). Although these subunit vaccine candidates offer safety advantages over the use of live-attenuated strains and OMVs, none has been able to provide complete protection and sterilizing immunity when tested alone (16).

Since CPS is structurally conserved and expressed by all known virulent isolates of *B. pseudomallei*, it is an attractive antigen for vaccine development (26, 30). Supporting this, CPS-specific monoclonal antibodies (MAbs) have been used to passively immunize mice against lethal challenges of *B. pseudomallei* (21, 28). Recently, we showed that immunization of BALB/c mice with a CPS-cBSA (cationized bovine serum albumin) glycoconjugate resulted in high CPS-specific IgG titers that conferred significant protection against a *B. pseudomallei* challenge (26). In addition, we have shown that when immunized with a combination of CPS-cBSA and recombinant LolC, mice exhibit higher...
survival rates when challenged with a lethal intraperitoneal dose of \( B. \) pseudomallei compared to mice immunized with each component alone (26). Based upon these observations, we believe that a subunit vaccine formulation that stimulates both protective humoral and cellular immune responses can be developed to provide full protection against \( B. \) pseudomallei infections.

In the present study, we used a combination of molecular genetic, biochemical, and immunological approaches to evaluate the immunogenicity and protective capacity of a CPS-based glycoconjugate combined with either a hemolysin coregulated protein (Hcp1) or a deubiquitinase (TssM). Here, we demonstrate for the first time that subunit vaccine formulations containing these antigens provide C57BL/6 mice with high-level protection and sterilizing immunity against acute inhalational challenge with \( B. \) pseudomallei.

**RESULTS**

**Synthesis of CPS-CRM197.** To construct the glycoconjugate material used in this study, the 6-deoxyheptan CPS from \( B. \) pseudomallei RR2683 (select agent excluded strain) was isolated by using a hot aqueous-phenol extraction method (30, 31). The purified CPS was then oxidized and covalently linked to CRM197 diphtheria toxin mutant (CRM197) via reductive amination to produce CPS-CRM197 (Fig. 1a). To optimize conjugation of the CPS to CRM197, small-scale reactions (with mixtures containing 5 mg CPS plus 2.5 mg CRM197) were initially conducted in phosphate-buffered saline (PBS; pH 7.2) or borate buffer (BB; pH 8.5). At various time points during the coupling reactions, samples were drawn and examined by SDS-PAGE (Fig. 1b). As indicated by shifts in molecular weights of the conjugate material relative to CRM197 controls, the results demonstrated that the CPS covalently linked to the carrier protein in a time-dependent manner. Reaction of the CPS with CRM197 was found to be most efficient in BB, with the majority of the carrier protein being coupled by day 10. Interestingly, while the conjugate material synthesized in BB was isolated in a soluble form, most of the conjugate material produced in PBS ended up as an insoluble precipitate. Based on
these observations, a large-scale reaction of CPS (20 mg) with CRM197 (10 mg) was conducted using BB as the solvent system. Upon termination of the reaction, the yield of CPS-CRM197 was determined to be 23.3 mg (~77% of the starting material). Analysis of the glycoconjugate material revealed that it contained 60% (wt/wt) CPS and 52 endotoxin units (EU)/mg as determined by protein and endotoxin assays, respectively. Similar to previous studies, Western immunoblotting confirmed that the structural integrity and antigenicity of the CPS remained intact following chemical activation and linkage to the carrier protein, based upon strong reactivity with MAb 3C5 (see Fig. S1 in the supplemental material) (30).

**Production of recombinant Hcp1 and TssM.** To obtain recombinant Hcp1 and TssM for use in the present study, N-terminal His-tagged versions of these proteins were expressed and purified from *E. coli*. Like our previous studies, the Hcp1 and TssM antigens were extracted from whole-cell pellets in a soluble form and purified to homogeneity using tandem nickel-cobalt chromatography (32–34). SDS-PAGE was used to assess the purity and structural integrity of the antigens (Fig. S2). Endotoxin concentrations associated with the Hcp1 and TssM preparations were 0.20 and 0.49 EU/mg, respectively, as determined in a *Limulus* amoebocyte lysate (LAL) assay.

**Analysis of antibody responses raised against CPS-CRM197, Hcp1, and TssM.** To assess the immunogenic potential of our vaccine antigens, groups of C57BL/6 mice were immunized with (i) adjuvant only, (ii) CPS-CRM197, (iii) Hcp1, (iv) TssM, (v) CPS-CRM197 plus Hcp1, or (vi) CPS-CRM197 plus TssM. One week after the final boost, serum was collected from the mice, and antigen-specific IgM and IgG titers were determined in an enzyme-linked immunosorbent assay (ELISA). As expected, the conjugate (whether alone or in combination with Hcp1 or TssM) stimulated the production of a high-titer IgM response (endpoint titers of ≥10^3) and a total IgG response (endpoint titers of ≥10^5) against CPS (Fig. 2a). Similarly, the recombinant *Burkholderia* proteins (whether alone or in combination with CPS-CRM197) stimulated the production of high-titer IgM (endpoint titers of ≥10^3) and total IgG (endpoint titers of ≥10^6) responses against Hcp1 and TssM (Fig. 2b and c). Additionally, analysis of the immune serum samples revealed that balanced Th2/Th1-type responses were raised against all antigens based on the IgG1:IgG2b ratios (Fig. 2a to c) (35, 36).

To assess the functionality of the CPS- and protein-specific antibodies, opsonophagocytosis assays were conducted. As shown in Fig. 3, preincubation of *B. pseudomallei* K96243 with heat-inactivated (HI) pooled antiserum from mice immunized with CPS-CRM197, CPS-CRM197 plus Hcp1, or CPS-CRM197 plus TssM significantly enhanced bacterial uptake into RAW 264.7 cells (>5-fold) compared to responses in mice administered nonconjugate antiserum controls. When serum obtained from groups of mice immunized with adjuvant only, Hcp1, or TssM was evaluated in the same assays, no differences in uptake levels were observed in comparison to the medium-only controls. Taken together, these results demonstrate that the conjugate material used in our vaccine formulations was capable of stimulating opsonizing antibody responses in C57BL/6 mice.

**Analysis of cellular immune responses against CPS-CRM197, Hcp1, and TssM.** One week after the final boost, single-cell suspensions were prepared from the spleens of immunized mice and restimulated with the various vaccine antigens. Enzyme-linked immunosorbent spot (ELISpot) assays were then used to analyze T cell responses. Since CRM197 is a well-characterized T cell-dependent antigen, splenocytes isolated from mice immunized with CPS-CRM197, CPS-CRM197 plus Hcp1, or CPS-CRM197 plus TssM significantly enhanced bacterial uptake into RAW 264.7 cells (>5-fold) compared to responses in mice administered nonconjugate antiserum controls. When serum obtained from groups of mice immunized with adjuvant only, Hcp1, or TssM was evaluated in the same assays, no differences in uptake levels were observed in comparison to the medium-only controls. Taken together, these results demonstrate that the conjugate material used in our vaccine formulations was capable of stimulating opsonizing antibody responses in C57BL/6 mice.
cyte preparations from mice in the CPS-CRM197 plus TssM group had significantly lower numbers of IFN-γ-secreting T cells than mice immunized with CPS-CRM197 or CPS-CRM197 plus Hcp1 (Fig. 4a). Furthermore, when splenocytes from mice immunized with CPS-CRM197 plus Hcp1 were restimulated with Hcp1, fewer IFN-γ-secreting T cells were detected than in the mice immunized with Hcp1 only (Fig. 4b). No significant differences were observed, however, between the T cell responses obtained from mice immunized with either CPS-CRM197 plus TssM or TssM only when restimulated with TssM (Fig. 4c). Collectively, these findings demonstrate that robust IFN-γ-secreting T cell responses can be raised against the *Burkholderia* protein antigens used in this study.

**Animal challenge studies.** The ultimate goal of this study was to assess the abilities of the various antigens to protect immunized mice against a lethal bacterial challenge. To facilitate this, we first had to establish a median 50% lethal dose (LD_{50}) for our *B. pseudomallei* isolate, using appropriately aged mice. This was accomplished by challenging 16- to 18-week-old C57BL/6 mice with various doses of *B. pseudomallei* K96243 via an inhalational route and monitoring their survival for 35 days (Fig. S3). Upon termination of the experiment, we calculated the LD_{50} to be 154 CFU. Once this had been accomplished, immunized mice were challenged with ~10 LD_{50} of K96243 5 weeks after the final boost and monitored for signs of morbidity and mortality over a 35-day period. As expected, all mice in the adjuvant-only group succumbed rapidly to infection (≤8 days). In contrast, groups immunized with CPS-CRM197 (whether alone or in combination with Hcp1 or TssM) exhibited survival rates that were significantly
different from the adjuvant control (Fig. 5a and b). Specifically, immunization of mice with CPS-CRM197 plus Hcp1 resulted in 100% survival, while immunization with CPS-CRM197 plus TssM or CPS-CRM197 alone resulted in 80% and 67% survival, respectively. Interestingly, only 30% and 20% of the mice immunized with Hcp1 or TssM, respectively, survived the full duration of the study.

**FIG 3** Functional analysis of antibody responses raised against CPS-CRM197, Hcp1, and TssM. C57BL/6 mice (*n* = 6 per group) were immunized on days 0, 21, and 35 with adjuvant only (Alhydrogel/CpG), conjugate only, Hcp1 only, TssM only, conjugate plus Hcp1, and conjugate plus TssM. Immune serum samples were collected on day 42. *B. pseudomallei* K96243 was incubated with (a) medium only (no-serum control), pooled HI adjuvant (Alhydrogel/CpG)-only immune serum, pooled HI conjugate-only immune serum, pooled HI conjugate plus Hcp1-immune serum, or (b) medium only (no-serum control), pooled HI adjuvant (Alhydrogel/CpG)-only immune serum, pooled HI conjugate-only immune serum, pooled HI TssM-only immune serum, or pooled HI conjugate plus TssM immune serum. Following incubation for 1 h, opsonized bacteria were added to RAW 264.7 murine macrophage monolayers. Uptake was quantitated at 3 h postinfection. Reported values represent mean results ± standard deviations for three individual assays conducted in triplicate. Figures are representative of at least three independent experiments conducted on different days. ns, not significant; *, *P* < 0.05.

**FIG 4** Characterization of cellular immune responses raised against CPS-CRM197, Hcp1, and TssM. C57BL/6 mice (*n* = 4 per group) were immunized on days 0, 21, and 35 with adjuvant only (Alhydrogel/CpG), conjugate only, Hcp1 only, TssM only, conjugate plus Hcp1, or conjugate plus TssM. Spleens were harvested on day 42, and IFN-γ-secreting T cell responses against (a) CPS-CRM197, (b) Hcp1, and (c) TssM were quantitated in an ELISpot assay. Black dots represent the mean results of assays conducted in duplicate for individual mice. Black bars represent geometric means for a group. ns, not significant; *, *P* < 0.05.
To further investigate the protective capacity of our vaccine formulations, survivors were culled at day 35, and tissue samples from lungs, livers, and spleens were plated to quantitate bacterial loads. As shown in Fig. 5c, 7/10 of the mice immunized with CPS-CRM197 plus Hcp1 had no culturable bacteria in any of their tissues. Interestingly, while mouse 2 from this group was shown to have high bacterial loads in its lungs, there was no evidence of dissemination to its liver or spleen. Results also demonstrated that 5/8 of the mice immunized with CPS-CRM197 plus TssM and 4/6 of the mice immunized with CPS-CRM197 plus Hcp1 had no culturable bacteria in their tissues, with the remaining mice showing low bacterial loads. These results highlight the protective efficacy of these vaccine formulations in preventing dissemination of the pathogen.
immunized with CPS-CRM197 had no detectable bacteria in their tissues. Remarkably, no bacteria were isolated from the spleens of any of the mice. Consistent with these findings, histopathological analyses revealed that the lungs, livers, and spleens from survivors in the group immunized with CPS-CRM197 plus Hcp1 (mice 1 to 5) were unremarkable and presented as normal healthy tissue with normal architecture (Fig. 6; Table S1). Taken together, these studies demonstrated the vaccinogenic potential of our antigen formulations. Additionally, they showed that immunization of C57BL/6 mice with CPS-CRM197 plus Hcp1 resulted in 100% survival and 70% sterilizing immunity following an acute inhalational challenge with B. pseudomallei.

**DISCUSSION**

Melioidosis is now increasingly recognized as an important cause of morbidity and mortality worldwide, yet no licensed vaccines currently exist to prevent disease in humans or animals (1, 16). Since B. pseudomallei is a facultative intracellular pathogen, protective immunity is likely complex, requiring a combination of humoral and cell-mediated responses. To address this, studies in our laboratories have been focused on the development of subunit vaccines that incorporate a combination of protective polysaccharide and protein antigens (26, 29). The rationale for this approach is that when appropriately adjuvanted, such vaccines should be able to stimulate both protective antibody and T cell responses. Additionally, since these types of vaccines are antigenically defined, they can be designed to minimize the safety issues and undesirable side effects often associated with the use of whole-cell or live attenuated vaccines. In the present study, we provided strong evidence that our subunit vaccines can protect mice against an acute inhalational challenge with B. pseudomallei. Collectively, our results help to better establish surrogates of antigen-induced immunity against this important bacterial pathogen, as well as provide valuable insights toward the development of an antigenically defined, safe, affordable, and effective melioidosis vaccine (39).

The 6-deoxyheptan CPS is an attractive vaccine candidate because it is (i) a requisite virulence factor, (ii) structurally conserved, and (iii) expressed by all known virulent isolates of B. pseudomallei (40). Additionally, several passive and active immunization studies have proven it to be a protective antigen (21, 28). Notably, we previously showed that immunization of BALB/c mice with a CPS-cBSA conjugate provided significant protection against lethal intraperitoneal challenges with B. pseudomallei (26). While this earlier study was an important first step in demonstrating the vaccinogenic potential of CPS, we recognized that there were limitations regarding the use of animal proteins to develop human vaccines. In the present study, therefore, we wanted to

---

**FIG 6** Histopathological analysis of mouse tissues following a lethal inhalational challenge with B. pseudomallei. Following termination of the challenge study, lungs, livers, and spleens were harvested from five mice (numbers 1 to 5) of the 10 survivors that had been immunized with CPS-CRM197 plus Hcp1. The tissues were fixed and stained with H&E. Images are representative of all 5 mice. Original magnification, ×400.
identify a carrier that would facilitate efficient production of a CPS-based glycoconjugate but, unlike cBSA, could also be licensed for use in humans.

There are five different carrier proteins currently used to produce human glycoconjugate vaccines: tetanus toxoid (T), meningococcal outer membrane protein complex (OMPC), *Haemophilus influenzae* protein D (HiD), diphtheria toxoid (D), and CRM197 (41). Of these, CRM197 is considered the most versatile, since it has multiple lysyl side chains that are available for coupling with activated polysaccharides (41). Based on this, we elected to produce our conjugates using recombinant CRM197 (38). Initial attempts to conjugate CPS to CRM197 using PBS as a solvent system resulted in less-than-optimal conjugation and the formation of insoluble precipitates. To resolve these issues, we switched to a BB solvent system, which resulted in high-efficiency coupling and the production of soluble conjugate material that could be filter sterilized (42).

It is well established that capsular polysaccharides enable many bacterial pathogens to evade uptake and killing by phagocytic cells (43). It is also well established that CPS-based glycoconjugate vaccines can induce opsonizing antibody responses to combat disease caused by such organisms (44, 45). The intended purpose of the glycoconjugate material in our vaccine formulations, therefore, was to stimulate the production of opsonizing antibody responses against the CPS antigen. When immunized with CPS-CRM197, either alone or in combination with Hcp1 or TssM, C57BL/6 mice were found to generate high-titer CPS-specific IgG responses. Such findings are consistent with previous studies in which CPS-cBSA was used as an immunogen, and our findings confirmed that T cell-dependent-type antibody responses are being raised against the polysaccharide portion of CPS-CRM197 (46). Extending upon these findings, we also investigated the opsonizing capacity of the immune serum samples. As anticipated, our results demonstrated that CPS-specific antibodies, whether alone or in combination with Hcp1- or TssM-specific antibodies, were functional and promoted uptake of *B. pseudomallei* into RAW 264.7 cells. These findings are consistent with several previous studies demonstrating that CPS-specific monoclonal antibodies and/or polyclonal antiserum enhances uptake of *B. pseudomallei* and/or *B. mallei* into phagocytic cells (28, 30, 47, 48).

A variety of proteins have been explored for their vaccinogenic potential in animal models of melioidosis. Varied results have been achieved, with no single antigen providing high-level protection against acute challenges with *B. pseudomallei* (16). Recently, we demonstrated that when BALB/c mice were immunized with a combination of CPS-cBSA and recombinant LolC, rather than with CPS-cBSA or LolC individually, they exhibited higher survival rates when challenged with a lethal dose of *B. pseudomallei* (26). In the present study, we extended upon this finding by investigating the protective capacity of two different *Burkholderia* proteins combined with CPS-CRM197 in C57BL/6 mice. The proteins selected for this purpose were Hcp1 and TssM. Hcp1 is a major structural component of the virulence-associated *B. pseudomallei* type VI secretion system and is expressed at high levels upon activation of this system (32, 49). TssM is a potent deubiquitinase involved in modulating host immune responses and is secreted by *B. pseudomallei* in a type II secretion system-dependent manner (34, 50). These proteins were chosen because (i) they are highly conserved among *B. pseudomallei* isolates, (ii) they are known to be expressed in humans during active infections with the organism, and (iii) Hcp1 is a known protective antigen in animal models of experimental melioidosis (32, 51). In addition to these important attributes, recombinant Hcp1 and TssM are both “well-behaved” proteins that can be expressed at high levels in *Escherichia coli* and purified in a soluble form, and they are stable for extended periods of time when stored at 4°C (data not shown). When immunized with recombinant Hcp1 or TssM, either alone or in combination with CPS-CRM197, C57BL/6 mice were found to produce high-titer IgG responses (endpoint titers of \( \geq 10^9 \)) against the proteins. Such results indicated that Hcp1 and TssM are highly immunogenic antigens.

Since *B. pseudomallei* is capable of surviving and replicating within host cells, it is reasonable to predict that cell-mediated immune responses are important for controlling infections caused by this pathogen. For instance, *B. pseudomallei* protein-specific
IFN-γ-secreting T cells are likely required to promote efficient clearance of the organism following uptake by macrophages. Supporting this, recent studies have demonstrated a correlation between survival of melioidosis patients and enhanced T cell immunity to specific B. pseudomallei antigens (52, 53). Thus, the intended purpose of the Burkholderia proteins in our vaccine formulations was to stimulate the production of Hcp1- and TssM-specific IFN-γ-secreting T cell responses. Results of ELISpot assays demonstrated that robust IFN-γ-secreting T cell responses were observed in both Hcp1- and TssM-immunized mice. Interestingly, when Hcp1 was combined with CPS-CRM197, the Hcp1-specific T cell responses were significantly lower than those in mice immunized with only Hcp1. At present, the reason for this phenomenon is unclear. Further studies are required to better understand this effect as well as determine whether it may influence vaccine efficacy. In addition to this, studies will be required to confirm which T cell populations (i.e., CD4⁺, CD8⁺, or both) are activated by the Burkholderia proteins, as well as what role(s) they might be playing in controlling B. pseudomallei infections.

Following three doses of the vaccine formulations, C57BL/6 mice were challenged with lethal inhalational doses (≈10 LD₅₀) of B. pseudomallei K96243. This challenge route was chosen to evaluate the protective capacity of our vaccine antigens, since it represents a natural route of infection and would also be the most likely mode of exposure in the event of a deliberate release of the organism (54). When used alone, Hcp1 and CPS-CRM197 were shown to provide different degrees of protection (30% and 67% survival, respectively). Supporting our hypothesis that optimal protection likely requires both humoral and cellular immune responses, combining the antigens yielded an observable synergistic effect. Specifically, 100% of the mice immunized with CPS-CRM197 plus Hcp1 survived the full duration of the study. Although protection afforded by the antigen combination was not statistically different than that by CPS-CRM197 alone, there was a clear biological advantage associated with the use of this formulation. A major challenge in developing vaccines to combat disease caused by facultative intracellular pathogens is the host’s ability to achieve sterilizing immunity (16, 55). Based upon the results of this study, there is compelling evidence that our lead vaccine formulation (CPS-CRM197 plus Hcp1) may be able to accomplish this goal. To our knowledge, this is the highest level of protection conferred by a subunit vaccine against an acute inhalational challenge with B. pseudomallei.

Collectively, these studies support our rationale for developing multivalent subunit vaccines to immunize against disease caused by B. pseudomallei. Considering that high-level protection was achieved against an acute inhalational challenge, we predict that such vaccines will be useful for both public health and biodefense purposes. Studies are ongoing to confirm our findings, optimize the protective capacity of our lead formulation, and define specific surrogates of antigen-induced immunity in both C57BL/6 (the prototypical Th1 strain) and BALB/c (the prototypical Th2 strain) mouse models of acute melioidosis.

MATERIALS AND METHODS

Bacterial strains, plasmids, and growth conditions. Bacterial strains and plasmids used in this study are described in Table 1. Escherichia coli strains with plasmids were cultured on Luria-Bertani–Lennox (LB; Fisherbrand) agar or in LB broth containing ampicillin (100 µg/ml). B. pseudomallei RR2683 was cultured in LB broth or on LB agar supplemented with thiamine (5 µg/ml) and adenine (100 µg/ml). B. pseudomallei K96243 was cultured in LB broth or on LB agar. All bacterial cultures were incubated at 37°C; broth cultures were incubated with shaking (200 rpm). Bacterial stocks were maintained at −80°C as 20% glycerol suspensions. All manipulations of B. pseudomallei K96243 were conducted in CDC- and USDA-approved and registered biosafety level 3 (BSL3) or animal biosafety level 3 (ABSL3) facilities at the University of South Alabama or the University of Texas Medical Branch, and experiments were performed in compliance with the rules and regulations of the U.S. Federal Select Agent Program.

CPS purification. Broth in 2-liter baffled Erlenmeyer flasks was inoculated with B. pseudomallei RR2683 and incubated overnight at 37°C with shaking (200 rpm). Cell pellets were obtained by centrifugation and extracted using a modified hot aqueous phenol procedure (31). Purified CPS antigens were then obtained essentially as previously described (30, 56).

Glycoconjugate synthesis. Recombinant, preclinical-grade CRM197 was purchased from Reagent Proteins. The CPS-CRM197 glycoconjugates used in this study were synthesized essentially as previously described (30, 56). Briefly, purified CPS was solubilized at 5 mg/ml in PBS (BupH; Pierce) and added to a small amber vial. To each milliliter of the CPS solution was added ~6 mg (~30 mM) of sodium...
January 2018 Volume 86 Issue 1 e00724-17

**TABLE 1** Bacterial strains and plasmids used in this study

| Strain or plasmid | Descriptiona | Reference or source |
|-------------------|--------------|---------------------|
| **Escherichia coli** strain | | |
| TOP10 | Lab strain for cloning and protein expression | Life Technologies |
| **Burkholderia pseudomallei** strains | | |
| RR2683 | OPS-deficient derivative of select agent excluded strain Bp82; ΔpurM ΔamlD 61 |
| K96243 | Wild type; clinical isolate from Thailand 62 |
| **Plasmids** | | |
| pBAD/HisA | Arabinose inducible, 6×His tag expression vector; Ap′ Life Technologies |
| pBAD/Bmphcp1-6HisF | pBAD/HisA containing *B. mallei* hcp1 (BMAA0742) with an N-terminal His tag 33 |
| pMB1000 | pUC57Kcontaining *B. pseudomallei* tsSM (BPSS1512) corresponding to amino acids 191–474 in which Cys codon (TGC) at position 102 in TsSM changed to Gly codon (GGC) This study |
| pMB1001 | pBAD/HisA containing *B. pseudomallei* tsSM (BPSS1512) corresponding to amino acids 191–474 in which Cys codon (TGC) at position 102 in TsSM changed to Gly codon (GGC); N-terminal His tag This study |

aAp′, ampicillin resistance.

metaperiodate. Once the crystals had dissolved, the reaction mixture was incubated for ∼40 min at room temperature with stirring. To remove any excess oxidizing agent, the reaction mixture was applied to a Zeba Desalt spin column (Pierce) equilibrated with either PBS or BB (Pierce), and the eluate was collected. To facilitate conjugation of CPS to the carrier protein (CRM197 buffer exchanged at 5 mg/ml into either PBS or BB on a Zeba column), the activated CPS was added to a small amber vial. To each milliliter of the CPS solution was added 500 μl of the carrier protein (5-mg/ml stock). Following mixing by gentle agitation, 10 μl of a 1 M sodium cyanoborohydride stock (in 10 mM NaOH) was added to each milliliter of the conjugation mixture, and the reaction mixture incubated at 37°C for 10 days with stirring. The conjugate reaction mixture was then dialyzed against distilled H2O using a 3,500-molecular weight cutoff Slide-A-Lyzer cassette (Pierce), sterilized with a syringe filter (0.45 μm), and lyophilized. A bicinchoninic acid (BCA) assay (Pierce) was used to quantitate the protein concentration of the glycoconjugate stock (and the remainder of the mass was assumed to be polysaccharide).

**Protein expression and purification.** Recombinant Hcp1 harboring an N-terminal 6×His tag was purified from *E. coli* TOP10 (pBAD/Bmphcp1-6HisF) as previously described (33). For expression of recombinant TsSM with an N-terminal 6×His tag, the tsSM open reading frame (BPSS1512) in which the Cys codon (TGC) at position 102 in TsSM was changed to a Gly codon (GGC) was cloned into pBAD/HisA (34). Briefly, plasmid pMB1000 (synthesized at GenScript, Piscataway, NJ) was digested with Ncol and HindIII to release the tsSM-G102 insert, which was then cloned into similarly digested pBAD/HisA to produce pMB1001. Recombinant DNA techniques were conducted as previously described (49). DNA sequencing was performed by ACGT Inc. TsSM was purified from *E. coli* TOP10 (pMB1001) essentially as previously described for Hcp1 (33). The purities of Hcp1 and TsSM were verified by SDS-PAGE. Protein concentrations were determined using a BCA protein assay kit (Pierce). Endotoxin removal was performed using high-capacity endotoxin removal resin (Pierce) per the manufacturer’s instruction. The amounts of endotoxin in the Hcp1 and TsSM preparations were quantitated by using an LAL chromogenic endotoxin quantitation kit (Pierce) per the manufacturer’s instruction. Proteins were sterilized with a syringe filter (0.45 μm) and stored at 4°C.

**SDS-PAGE and Western immunoblotting.** Glycoconjugate samples were solubilized in 1× SDS-PAGE sample buffer and heated to 100°C for 5 min prior to electrophoresis on 4-to-20% Tris-HEPES gels (Pierce). Proteins were visualized via staining with Coomassie blue R-250. For Western immunoblotting, the glycoconjugate samples and controls were separated on the same 4-to-20% gels and electrophoretically transferred to nitrocellulose membranes. The membranes were blocked with 3% skim milk in high-salt Tris-buffered saline (HS-TBS; 20 mM Tris, 500 mM NaCl; pH 7.5) for 60 min at room temperature and then incubated for 1 h at room temperature with a 1/1,000 dilution of a *B. pseudomallei* CPS-specific MAb (3CS) (57). To facilitate detection, the membranes were incubated for 1 h at room temperature with 1/5,000 dilutions of an anti-mouse IgG-horseradish peroxidase conjugate (Southern Biotech). Blots were visualized using the Pierce ECL Western blotting substrate (Thermo Scientific) and a ChemiDoc XRS imaging system (Bio-Rad).

**Ethics statement.** All investigations involving animals were conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council (58), Protocols were approved by the Animal Care and Use Committees at the University of South Alabama (protocol 488113) or the University of Texas Medical Branch (protocol 0503014D). Mice were housed in microisolator cages under pathogen-free conditions, provided with rodent feed and water ad libitum, and maintained on a 12-h light cycle.

**Mouse immunizations.** Groups of 6- to 8-week-old female C57BL/6 mice (*n* = 16 per group; Charles River) were immunized subcutaneously on days 0, 21, and 35 with the following antigens: CPS-CRM197 (2.5 μg/dose of CPS as a conjugate), Hcp1 (5 μg/dose), TsSM (5 μg/dose), CPS-CRM197 plus Hcp1, or CPS-CRM197 plus TsSM. All antigens were formulated in tissue culture-grade PBS (pH 7.2; Gibco) with
Alhydrogel 2% (500-µg/dose; Brenntag) and CpG (20-µg/dose; ODN 2006; Invivogen) as the adjuvant system. Mice immunized with adjuvant only served as controls.

**Analysis of antibody titers.** Terminal bleeds (n = 6 mice per group) were conducted 1 week after the final boost. Serum was stored at −80°C until required for use. Antibody responses directed against the vaccine antigens were assessed by ELISAs essentially as previously described (9, 56). Briefly, 96-well Maxisorp plates (Nunc) were coated overnight at 4°C with purified CPS, Hcp1, or TssM (1 µg/ml) solubilized in carbonate buffer (pH 9.6). The plates were blocked at room temperature for 30 min with StartingBlock T20 (TBS) blocking buffer (Pierce) and then incubated for 2 h at 37°C with the mouse serum samples serially diluted in Tris-buffered saline plus 0.05% Tween 20 (TBS-T; pH 7.5) plus 10% Starting-Block T20. To facilitate detection, the plates were incubated for 1 h at 37°C with 1/2,000 dilutions of anti-mouse IgM, IgG, IgG1, or IgG2b horseradish peroxidase-conjugated antibodies (Southern Biotech). The plates were developed with tetramethylbenzidine substrate (KPL) and read at 620 nm by using a FLUOstar Omega microplate reader (BMG Labtech). The reciprocals of the highest dilutions exhibiting optical densities that were 3 times the background levels were used to determine the endpoint titers for individual mice.

**Opsonophagocytosis assays.** The murine macrophage cell line RAW 264.7 (ATCC TIB-71) was maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% (vol/vol) HI fetal bovine serum (DMEM-10; Invitrogen) and a standard mixture of antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin, and 250 µg/ml amphotericin B; Sigma) at 37°C under an atmosphere of 5% CO2. Opsonophagocytosis assays were performed essentially as previously described (30). Briefly, RAW 264.7 cells resuspended in DMEM-10 were transferred into 24-well tissue culture plates at a density of 1 × 105 cells/well and incubated overnight. *B. pseudomallei* K96243 cultures grown to early log phase were pelleted, resuspended at a density of 1 × 10^9 CFU/ml in DMEM or DMEM containing 1% adjuvant only, Hcp1, TssM, CPS-CRM197, CPS-CRM197 plus Hcp1, or CPS-CRM197 plus TssM mouse immune serum (pooled and HI for 30 min at 56°C) and then incubated at 37°C for 1 h. RAW 264.7 monolayers were washed twice with Hank’s balanced salts solution (HBSS; Invitrogen) prior to the addition of the opsonized bacterial suspensions. The monolayers were incubated with the bacteria for 1 h at 37°C under an atmosphere of 5% CO₂ and then washed twice with HBSS to remove extracellular bacteria. Infected RAW 264.7 cells were incubated with fresh DMEM-10 containing 25 µg/ml kanamycin to suppress the growth of residual extracellular bacteria. At 3 h postinfection, the infected monolayers were washed twice with HBSS and lysed with 0.2% (vol/vol) Triton X-100 (Sigma), and serial dilutions of the lysates were plated onto LB agar plates and incubated at 37°C for 48 h. Plate counts were used to enumerate bacterial loads.

**ELISpot assays.** Spleens (from 4 mice per group) were harvested 1 week after the final boost from terminally bled mice. Single-cell suspensions were prepared by passing the organs through 70-µm cell strainers (Falcon) into RPMI 1640 (Gibco) supplemented with 10% (vol/vol) HI fetal bovine serum and 1× penicillin/streptomycin (Gibco) (RPMI-10). Cells were pelleted by centrifugation (500 × g), resuspended in red blood cell lysis solution (Sigma), incubated at room temperature for 10 min, pelleted (500 × g), and then resuspended in RPMI-10 at a concentration of 5 × 10^6 cells/ml. Mouse IFN-γ ELISpot kits (R&D Systems) were used per the manufacturer’s instructions. Splenocytes stimulated with CPS-CRM197, Hcp1, TssM, or medium only were added to the plates at a concentration of 2.5 × 10^5 cells/well and then incubated for 48 h at 37°C under an atmosphere of 5% CO₂. The ELISpot plates were processed and developed per the manufacturer’s instructions. Plates were imaged using an ImmunoSpot S1 analyzer (Cellular Technology Ltd.). IFN-γ-secreting T cells were quantitated using the ImmunoSpot v5.1 professional DC smart count software (Cellular Technology Ltd.).

**LD₅₀ determinations.** Groups of 16- to 18-week-old female C57BL/6 mice (Charles River Laboratories) were housed in standard microisolator cages and were provided water and food *ad libitum*. Mice were acclimated to housing for at least 7 days prior to bacterial infection. The LD₅₀ for *B. pseudomallei* K96243 was determined by exposing three groups of mice (n = 6 to 8 mice/group) to 67,728, and 53,500 CFU, as previously described (59). Mice were monitored for survival over 35 days, and the LD₅₀ was calculated using methods described by Reed and Muench (60).

**Mouse challenge studies.** Five weeks after the final boost (day 70), the remainder of the immunized mice (n = 10 per group) were challenged with *B. pseudomallei* K96243 at a nebulizer concentration of ~4.65 × 10^9 CFU/ml via aerosol, essentially as previously described (59). Briefly, three groups of 20 mice were exposed to aerosolized bacteria via a three-jet collision nebulizer for 15 min at a constant flow rate of 30 liters/min. During this automatically aerosol exposure, animals were restrained in a Biadera plastic aerosol rodent exposure box housed within a class III biological safety cabinet in a biosafety level 3 suite, using an automated aerosol exposure system. Animals were placed inside nose-only exposure restraint cones (In-Tox Products LLC, Moriarty, NM). Nebulizers were filled with 10 ml of LB broth containing the appropriate concentration of bacteria. Doses presented (Dp) to each group of animals were determined by performing standard CFU counts on the samples collected from an all-glass impinger (SKC BioSampler; SKC Inc., Eighty-Four, PA) containing LB broth with 4% glycerol and approximately 20 µl of antifoam 204 (Sigma-Aldrich). The Dp was calculated using the following formula: Dp (CFU) = C_surface (CFU per milliliter) × exposure time (in minutes) × minute volume (in milliliters); the minute volume = 2.1 (weight [in grams])^{0.75}. Weights and survival of the challenged mice were monitored for 35 days. Humane endpoints were strictly observed via daily monitoring throughout the study. Mice in the three challenge groups received Dp of 1,590, 1,650, and 1,550 CFU, which correlated with 10.3, 10.7, and 10.1 LD₅₀, respectively.
CFU enumeration and histological evaluation. At 35 days postchallenge, surviving animals were euthanized and their lungs, livers, and spleens were collected for CFU enumeration and histopathology. Half of each organ was fixed in 10% normal buffered formalin, and the remaining half was weighed and homogenized using Coviden Precision tissue grinders (Fisher Scientific). Tissue homogenates were serially diluted in PBS, plated, and incubated for 48 h at 37°C. Colonies were counted and normalized to organ weight (in grams). For histopathological analysis, fixed tissues were embedded in paraffin and sectioned prior to staining with hematoxylin and eosin (H&E). Pathology scoring was performed as previously described (59).

Statistical analysis. All graphs were produced by using GraphPad Prism 7.03 (GraphPad Software Inc.). Opsonophagocytosis and ELISpot data were analyzed using a Mann-Whitney U test. Survival data were analyzed using a log rank (Mantel-Cox) test.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/IAI.00724-17.

SUPPLEMENTAL FILE 1, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We thank Rosemary Roberts for technical assistance and David AuCoin for MAb 3C5. This research was supported by Defense Threat Reduction Agency contract HDTRA1-14-C-0023. D.D. was supported by DTRA/JSTO-CBD project number CBCALL12-LS1-2-0070.

The opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army in accordance with AR 70-31.

REFERENCES

1. Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Moyes CL, Rolim DB, Berthet E, Day NP, Peacock SJ, Hay SI. 2016. Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. Nat Microbiol 1:15008. https://doi.org/10.1038/nmicrobiol.2015.8.
2. Currie BJ, Kaestli M. 2016. Epidemiology: a global picture of melioidosis. Nature 529:290–291. https://doi.org/10.1038/529290a.
3. Dance DAB. 2000. Ecology of *Burkholderia pseudomallei* and the interactions between environmental *Burkholderia* spp. and human–animal hosts. Acta Trop 74:159–168. https://doi.org/10.1016/S0001-706X(99)00066-2.
4. Wiersinga WJ, van der Pol T, White NJ, Day NP, Peacock SJ. 2006. Melioidosis: insights into the pathogenicity of *Burkholderia pseudomallei*. Nat Rev Microbiol 4:272–282. https://doi.org/10.1038/nrmicro1385.
5. Chaouwagul W, White NJ, Dance DAB, Wattanagoon Y, Naigowit P, Davis TME, Looaressawan S, Pitakwattana N. 1989. Melioidosis: a major cause of community-acquired septicaemia in northeastern Thailand. J Infect Dis 159:890–899. https://doi.org/10.1093/infdis/159.5.890.
6. Currie BJ, Fisher DA, Howard DM, Burrow JNC, Lo D, Selva-nayagam S, Anstey NM, Huffman SE, Snelling PL, Marks PJ, Stephens DP, Lum GD, Jacups SP, Krause VL. 2006. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 31:981–986. https://doi.org/10.1086/318116.
7. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin Prospective Study. PLoS Negl Trop Dis 4:e900. https://doi.org/10.1371/journal.pntd.0000900.
8. Suputtamongkol Y, Chaouwagul W, Chetchotisakd P, Lertpatansawun N, Intarangnopai S, Ruchutrakool T, Budhsarawong D, Mootsikapun P, Wuthiekanun V, Teerawatasook N, Lulitanond A. 1999. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 29:408–413. https://doi.org/10.1086/318116.
9. Chen YL, Yen YC, Yang CY, Lee MS, Ho CK, Mena KD, Wang PY, Chen PS. 2014. The concentrations of ambient *Burkholderia pseudomallei* during typhoon season in endemic area of melioidosis in Taiwan. PLoS Negl Trop Dis 8:e2877. https://doi.org/10.1371/journal.pntd.0002877.
10. Cheng AC, Jacups SP, Gal D, Mayo M, Currie BJ. 2006. Extreme weather events and environmental contamination are associated with case-clusters of melioidosis in the Northern Territory of Australia. Int J Epidemiol 35:323–329. https://doi.org/10.1093/ije/dyj271.
11. Currie BJ, Jacups SP. 2003. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis 9:1538–1542. https://doi.org/10.3201/eid9012.020750.
12. Ko WC, Cheung BM, Tang HJ, Shih HI, Lau YJ, Wang LR, Chung YC. 2007. Melioidosis outbreak after typhoon, southern Taiwan. Emerg Infect Dis 13:896–898. https://doi.org/10.3201/eid1306.060646.
13. Currie BJ. 2015. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med 36:111–123. https://doi.org/10.1055/s-0034-1398389.
14. Rozt LD, Khan AS, Lillbridge SR, Ostroff SM, Hughes JM. 2002. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 8:225–230. https://doi.org/10.3201/eid0802.010164.
15. Vooskuhl GW, Cornea P, Brown RS, Greenfield RA. 2003. Other bacterial diseases as a potential consequence of bioterrorism: Q fever, brucellosis, glanders, and melioidosis. J Okla State Med Assoc 96:214–217.
16. Titball RW, Burtnick MN, Bancroft GJ, Brett P. 2017. *Burkholderia pseudomallei* and *Burkholderia mallei* vaccines: are we close to clinical trials? Vaccine 35: 5981–5989. https://doi.org/10.1016/j.vaccine.2017.03.022.
17. Atkins T, Prior R, Mack K, Russell P, Nelson M, Prior J, Ellis J, Oyston PC, Dougan G, Titball RW. 2002. Characterisation of an acapsular mutant of *Burkholderia pseudomallei* identified by signature tagged mutagenesis. J Med Microbiol 51:539–547. https://doi.org/10.1099/0022-1317-51-7-539.
18. Nieves W, Asakrah S, Qazi O, Brown KA, Kurtz J, Aucoin DP, McLachlan JB, Roy CJ, Morici LA. 2011. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary *Burkholderia pseudomallei* infection. Vaccine 29:8381–8389. https://doi.org/10.1016/j.vaccine.2011.08.058.
19. Nieves W, Petersen H, Judy BM, Blumentritt CA, Russell-Lodrigue K, Roy CJ, Torres AG, Morici LA. 2014. A *Burkholderia pseudomallei* outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol 21:747–754. https://doi.org/10.1128/CVI.00119-14.
20. Silva EB, Goodyear A, Sutherland MD, Podneyk NL, Gonzalez-Juarrero M, Schweizer HP, Dow SW. 2013. Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine. Infect Immun 81:4626–4634. https://doi.org/10.1128/IAI.00915-13.
21. AuCoin DP, Reed DE, Marlenee NL, Bowen RA, Thorkildson P, Judy BM, Torres AG, Kozel TR. 2012. Polysaccharide specific monoclonal antibody provide passive protection against intranasal challenge with *Burkholderia pseudomallei*. PLoS One 7:e35386. https://doi.org/10.1371/journal.pone.0035386.
22. Brett PJ, Woods DE. 1996. Structural and immunological characterization
of *Burkholderia pseudomallei* O-polysaccharide–flagellin protein conjugates. Infect Immun 64:2824–2828.

23. Bryan LE, Wong S, Woods DE, Dance DA, Chaowagul W. 1994. Passive protection of diabetic rats with antiserum specific for the polysaccharide portion of the lipopolysaccharide isolated from *Pseudomonas pseudomallei*. Can J Infect Dis 5:170–178. https://doi.org/10.1155/1994/856850.

24. Chinn CY, Tan SC, Nathan S. 2012. Immunogenic recombination *Burkholderia pseudomallei* MprA serum protein elicits protective immunity in mice. Front Cell Infect Microbiol 2:85. https://doi.org/10.3389/fcimb.2012.00085.

25. Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. 2007. Identification of a LoIC homologue in *Burkholderia pseudomallei*, a novel protective antigen for melioidosis. Infect Immun 75:4173–4180. https://doi.org/10.1128/IAI.00404-07.

26. Scott AE, Burtnick MN, Stokes MG, Whelan AO, Williamson ED, Atkins TP, Prior JL, Brett PJ. 2014. *Burkholderia pseudomallei* capsular polysaccharide conjugates provide protection against acute melioidosis. Infect Immun 82:3206–3213. https://doi.org/10.1128/IAI.01847-14.

27. Whitlock GC, Deeraaka A, Qazi O, Judy BM, Taylor K, Propst KL, Duffy AJ, Johnson K, Kitto GB, Brown KA, Dow SW, Torres AG, Estes DM. 2010. Protective response to subunit vaccination against intranasal *Burkholderia mallei* and *B. pseudomallei* challenge. Proc Natl Acad Sci U S A 107:71–75. https://doi.org/10.1073/pnas.0911298107.

28. Zhang S, Feng SH, Li B, Kim HY, Rodriguez J, Tsai S, Lo SC. 2011. In vitro and in vivo studies on monoclonal antibodies with prominent bactericidal activity against *Burkholderia pseudomallei* and *Burkholderia mallei*. Clin Vaccine Immunol 18:825–834. https://doi.org/10.1128/CVI.00533-10.

29. Muruato LA, Tapia D, Hatcher CL, Kalita M, Brett PJ, Gregory AE, Samuel JE, Titball RW, Torres AG, 13 September 2017. The use of reverse vaccinology in the design and construction of nano-glycoconjugate vaccines against *Burkholderia pseudomallei*. Clin Vaccine Immunol https://doi.org/10.1128/CVI.00206-17.

30. Burtnick MN, Heiss C, Roberts RA, Schweizer HP, Azadi P, Brett PJ. 2012. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol 2:108. https://doi.org/10.3389/fcimb.2012.00108.

31. Perry MB, MacLean LL, Schollaart T, Bryan LE, Ho M. 1995. Structural characterization of the lipopolysaccharide O antigens of *Burkholderia pseudomallei*. Infect Immun 63:3348–3352.

32. Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantrañita N, Scarpio A, Milne TS, Dean RE, Fritz DL, Peacock SJ, Prior JL, Atkins TP, Deshazer D. 2011. The cluster 1 type VI secretion system gene expression is negatively correlated with capsule in affecting the uptake and killing of *Burkholderia pseudomallei*. J Immunol Res 2014:392170. https://doi.org/10.1128/IAI.00533-10.

33. Pumpuang A, Dunachie SJ, Phokrai P, Jenjaroen K, Sintiprungrat K, Promwong C, Teparrukkul P, Limmathurotsakul D, Day NPJ, Altmann DM, Boynton RJ. 2013. Immune responses are associated with survival in acute melioidosis patients. J Infect Dis 207:2229–2233.

34. Weintraub A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr Res 338:2359–2357. https://doi.org/10.1016/j.carres.2003.07.008.

35. Lockhart S. 2003. Conjugate vaccines. Expert Rev Vaccines 2:633–648. https://doi.org/10.1586/14760584.2.5.633.

36. Snapper CM, Mond JJ. 1996. A model for induction of T cell-inherent humoral immunity in response to polysaccharide antigens. J Immunol 157:2229–2233.

37. Weib E, Ngugi SA, Laws TR, Corser D, Lonsdale CL, D’Elia RV, Titball RW, Williamson ED, Atkins TP, Prior JI. 2014. Protection against melioidosis following immunisation with a lipopolysaccharide-protein conjugate vaccine. J Immunol Res 2014:392170. https://doi.org/10.1128/2014/392170.

38. Mulye M, Bechill MP, Grose W, Ferreira VP, Lafontaine ER, Wooten RM. 2014. Delineating the importance of serum opsonins and the bacterial capsule in affecting the uptake and killing of *Burkholderia pseudomallei* by murine neutrophils and macrophages. PLoS Negl Trop Dis 8:e2988. https://doi.org/10.1371/journal.pntd.0002988.

39. Woodman ME, Worth RG, Wooten RM. 2012. Capsule influences the deposition of critical complement C3 levels required for the killing of *Burkholderia mallei* via NADPH-oxidase induction by human neutrophils. PLoS One 7:e32276. https://doi.org/10.1371/journal.pone.0032276.

40. Burtnick MN, Brett PJ, Williamson ED, Prior JL, Brett PJ. 2014. *Burkholderia mallei* as a vaccine candidate. Biochemical and biological characteristics of cross-reacting material 197. https://doi.org/10.3389/fvaccim.2014.00068.

41. Bryan LE, Huang C, Wang J, Lai R, Zeng Y, Yang Y, Zeng H, Chen H, Du Y, Wang L, Guerry P. 2009. Capsule polysaccharide conjugate vaccine against *Burkholderia pseudomallei* type II secretome reveals hydrolytic enzymes, novel proteins, and the deubiquitinase TssM. Infect Immun 77:6915–6920. https://doi.org/10.1128/IAI.01739-14.

42. Pasternack A, Lee S, Elder S, Majid SI, Raut M, Martin P, Titball RW, Atkins TP, Hackman RJ, Nurse RJ, Felgner PL, Huw Davies D, Wu T, Lyras D, Kozel KT, Neilson J. 2008. Identification of circulating bacterial antigens by in vitro and in vivo studies on monoclonal antibodies with prominent bactericidal activity against *Burkholderia pseudomallei* and *Burkholderia mallei*. Clin Vaccine Immunol 15:2229–2233.

43. Weintraub A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr Res 338:2359–2357. https://doi.org/10.1016/j.carres.2003.07.008.

44. Shanks J, Burtnick MN, Brett PJ, Waag DM, Spurgers K, Ribot WJ, Schell MA, Panchal RG, Gherardini FC, Wilkinson KD, DeShazer D. 2009. *Burkholderia mallei* tssM encodes a secreted deubiquitinase that is expressed inside infected RAW 264.7 cells. Infect Immun 77:1636–1648. https://doi.org/10.1128/IAI.01339-08.

45. Lefebre DJ, Benaina-Trouw B, Vliegenthart JF, Kamerling JP, Jensen WT, Krafte S, Klinke S, Snapper CM, Mond JJ. 1996. A model for induction of T cell-inherent humoral immunity in response to polysaccharide antigens. J Immunol 157:2229–2233.

46. Lin L, Gerth A, Peng SL. 2004. CpG DNA redirects class-switching towards “Th1-like” Ig isotype production via TLR9 and MyD88. Eur J Immunol 34:1483–1487. https://doi.org/10.1002/eji.200324736.

47. Brady C, Killeen K, Taylor W, Patkar A, Lees A. 2012. A new paradigm for rapidly translating novel conjugate vaccines into the clinic. Bioprocess Tech 10:50–55.

48. Broker M, Costantino P, DeTora L, McIntosh ED, Rappuoli R. 2011. Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 39:195–204. https://doi.org/10.1016/j.biologicals.2011.05.004.
vivo microbial antigen discovery. mBio 2:e00136-11. https://doi.org/10.1128/mBio.00136-11.

58. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.

59. Massey S, Yeager LA, Blumentritt CA, Vijayakumar S, Sbrana E, Peterson JW, Brasel T, LeDuc JW, Endsley JJ, Torres AG. 2014. Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection. Sci Rep 4:4305. https://doi.org/10.1038/srep04305.

60. Reed LJ, Muench H. 1938. A simple method for estimating fifty percent end points. Am J Hyg (Lond) 27:493–497.

61. Heiss C, Burtnick MN, Wang Z, Azadi P, Brett PJ. 2012. Structural analysis of capsular polysaccharides expressed by Burkholderia mallei and Burkholderia pseudomallei. Carbohydr Res 349:90–94. https://doi.org/10.1016/j.carres.2011.12.011.

62. Holden MTG, Titball RW, Peacock SJ, Cerdeño-Tárraga AM, Atkins T, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaiha M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P, DeShazer D, Feltwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabinowitsch E, Rutherford K, Sanders M, Simmonds M, Songsivilai S, Stevens K, Tumapa S, Vesaratchavest M, Whitehead S, Yeats C, Barrell BG, Oyston PCF, Parkhill J. 2004. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 101:14240–14245. https://doi.org/10.1073/pnas.0403302101.